Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer
Purpose: Complete and timely tissue genotyping is challenging, leading to significant
numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) …
numbers of patients with newly diagnosed metastatic non–small cell lung cancer (mNSCLC) …
[HTML][HTML] Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non–small-cell lung cancer
DR Spigel, TJ Ervin, RA Ramlau… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor
prognosis and acquired resistance to epidermal growth factor receptor (EGFR)–targeted …
prognosis and acquired resistance to epidermal growth factor receptor (EGFR)–targeted …
[HTML][HTML] Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non–small-cell lung cancer: CheckMate 153
DM Waterhouse, EB Garon, J Chandler… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–
small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a …
small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a …
[HTML][HTML] Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non–small cell lung cancer …
DR Spigel, M McCleod, RM Jotte, L Einhorn… - Journal of Thoracic …, 2019 - Elsevier
Abstract Introduction CheckMate 153 (NCT02066636) is a phase 3B/4 study assessing
nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria allowed …
nivolumab in previously treated patients with advanced NSCLC. Eligibility criteria allowed …
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non–small-cell lung cancer
DR Spigel, HA Burris III, FA Greco… - Journal of clinical …, 2011 - ascopubs.org
Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-
cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or …
cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or …
[HTML][HTML] Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II neoCOAST platform trial
Neoadjuvant chemoimmunotherapy improves pathologic complete response rate and event-
free survival in patients with resectable non–small cell lung cancer (NSCLC) versus …
free survival in patients with resectable non–small cell lung cancer (NSCLC) versus …
Three-year overall survival update from the PACIFIC trial.
JE Gray, AE Villegas, DB Daniel, D Vicente… - 2019 - ascopubs.org
8526 Background: In the phase 3 PACIFIC study of patients with unresectable, Stage III
NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated …
NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated …
[HTML][HTML] Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
S Bedrose, KC Miller, L Altameemi, MS Ali… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background There is no effective systemic therapy for metastatic adrenal cortical carcinoma
(ACC) after failure of platinum-based chemotherapy. The efficacies of single-agent oral …
(ACC) after failure of platinum-based chemotherapy. The efficacies of single-agent oral …
[HTML][HTML] Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-Care tissue testing in advanced non–small cell lung cancer
RD Page, LM Drusbosky, H Dada, VM Raymond… - Clinical Lung Cancer, 2022 - Elsevier
Background: Somatic genomic testing is recommended by numerous expert guidelines to
inform targeted therapy treatment for patients with advanced non-squamous non-small cell …
inform targeted therapy treatment for patients with advanced non-squamous non-small cell …
A phase II study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer (MBC)
DA Yardley, RR Young, KB Adelson, AL Silber… - Clinical breast …, 2022 - Elsevier
Background AR is a targetable pathway with AR modulation inhibiting estrogen-and
androgen-mediated cell proliferation. Orteronel is an oral, selective, nonsteroidal inhibitor of …
androgen-mediated cell proliferation. Orteronel is an oral, selective, nonsteroidal inhibitor of …